Are Lloyds Banking Group PLC And GlaxoSmithKline plc Bargain Buys For 2016?

Why Lloyds Banking Group PLC (LON:LLOY) and GlaxoSmithKline plc (LON:GSK) could reverse recent losses and beat the market in 2016.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Lloyds Banking Group (LSE: LLOY) and GlaxoSmithKline (LSE: GSK) may beat the FTSE 100 this year, but both stocks look likely to end the year lower than they started. Will they bounce back next year?

GlaxoSmithKline: On the rise

Shares in Glaxo are now down by nearly 25% from the highs seen in 2013. In fairness, this weakness has been justified by the firm’s recent financial performance, which has been disappointing.

Glaxo’s post-tax profits plunged from £5.436bn in 2013 to just £2.756bn in 2014 as the impact of patent losses on key products affected sales.

However, the situation does seem to be improving. Glaxo has now completed a major asset swap with Novartis and last week announced a new deal to acquire additional HIV products. Analysts expect full-year profits to rise by 34% to £3.691bn this year, and by a further 11% to £4.099bn in 2016.

The firm has managed to avoid cutting its dividend so far and currently offers a prospective yield of 6.1% for 2016. Big long-term backers of GlaxoSmithKline, such as star fund manager Neil Woodford, have been buying more shares this year.

Mr Woodford’s view is that short-term headwinds are overshadowing the much greater long-term earning power of Glaxo’s portfolio. This is a view I share.

For investors looking for long-term income and growth, I think that now could prove to be a good time to buy GlaxoSmithKline.

Lloyds: Stock overhang

I believe that Lloyds investors are suffering from a problem that more commonly affects shareholders in small cap companies – a stock overhang.

The overhang comes in the form of the government, which is gradually pumping its Lloyds shares back into the market. Since the end of May, the Treasury has sold 9% of Lloyds shares. That’s equivalent to £5.2bn worth of shares at today’s price.

This means that big institutional buyers of the stock have been guaranteed a good supply of Lloyds shares, without pushing up the price.

However, the share sale has been paused recently as Lloyds shares have been selling below 73.6p. This is the price at which the government bailed out Lloyds in 2008. The bankers handling the sale have been told only to sell Lloyds stock when the price is above this level.

I suspect that this requirement means Lloyds’ share price will find support at around 70p, as the volume of shares available for institutions to buy is much lower now that the government isn’t selling.

However, I also suspect that Lloyds shares won’t rise much above 73.6p until the government has sold all of its shares, which it hopes to do in 2016.

That’s why I believe now could be a good time to buy. At today’s price of 72p, Lloyds offers a prospective yield of 5.1% for 2016, and a modest forecast P/E of 9.5. The shares are supported by a book value of 68p and by 55p per share of tangible assets.

In my view Lloyds currently offers more upside potential than downside risk, and could prove a profitable buy for 2016.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle aged businesswoman using laptop while working from home
Investing Articles

Is Legal & General a top bargain after its 8% share price drop?

Looking for brilliant dividend shares to buy on the cheap? Royston Wild takes a look at Legal & General following…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Up 19% in a day, is there more to come from the surging Diploma share price?

Diploma’s share price is storming higher. But does the stock offer safety in an uncertain market, or is buying at…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

How much do you need in a Stocks and Shares ISA to target £2,000 a month of passive income?

With a bit of maths, our writer illustrates how an investor could shrink their initial ISA investment while supersizing dividend…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

The FTSE 100’s full of value shares at the moment. Here are 3 to consider

Recent events have taken their toll on the share prices of some of the UK’s biggest companies. But it also…

Read more »

Investing Articles

Should I buy beaten-down UK growth stocks today or conserve my cash for even bigger bargains?

Harvey Jones says the FTSE 100 is packed with cut-price growth stocks after recent volatility. Should investors buy now or…

Read more »

Number 5 foil balloon and gold confetti on black.
Investing Articles

£5,000 invested in Fresnillo shares 5 weeks ago is now worth…

Fresnillo shares have pulled back sharply from recent highs in the FTSE 100. Is this a chance to consider buying…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Down 15%, are Lloyds shares simply too cheap to miss now?

Have the wheels come off the long-term growth story for Lloyds Bank shares, or are they dipping into bargain territory…

Read more »

Business manager working at a pub doing the accountancy and some paperwork using a laptop computer
Investing Articles

Are investors taking a massive gamble by chasing the BP share price higher?

Investors who thought the BP share price would continue to rocket as the Iran war intensifies may have been surprised…

Read more »